Now showing items 1-20 of 44

    • Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study 

      Fendler, A; Shepherd, STC; Au, L; Wilkinson, KA; Wu, M; Byrne, F; Cerrone, M; Schmitt, AM; Joharatnam-Hogan, N; Shum, B; Tippu, Z; Rzeniewicz, K; Boos, LA; Harvey, R; Carlyle, E; Edmonds, K; Del Rosario, L; Sarker, S; Lingard, K; Mangwende, M; Holt, L; Ahmod, H; Korteweg, J; Foley, T; Bazin, J; Gordon, W; Barber, T; Emslie-Henry, A; Xie, W; Gerard, CL; Deng, D; Wall, EC; Agua-Doce, A; Namjou, S; Caidan, S; Gavrielides, M; MacRae, J; Kelly, G; Peat, K; Kelly, D; Murra, A; Kelly, K; O'Flaherty, M; Dowdie, L; Ash, N; Gronthoud, F; Shea, RL; Gardner, G; Murray, D; Kinnaird, F; Cui, W; Pascual, J; Rodney, S; Mencel, J; Curtis, O; Stephenson, C; Robinson, A; Oza, B; Farag, S; Leslie, I; Rogiers, A; Iyengar, S; Ethell, M; Messiou, C; Cunningham, D; Chau, I; Starling, N; Turner, N; Welsh, L; van As, N; Jones, RL; Droney, J; Banerjee, S; Tatham, KC; O'Brien, M; Harrington, K; Bhide, S; Okines, A; Reid, A; Young, K; Furness, AJS; Pickering, L; Swanton, C; Gandhi, S; Gamblin, S; Bauer, DL; Kassiotis, G; Kumar, S; Yousaf, N; Jhanji, S; Nicholson, E; Howell, M; Walker, S; Wilkinson, RJ; Larkin, J; Turajlic, S (NATURE PORTFOLIO, 2021-10-27)
    • Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. 

      Sundar, R; Miranda, S; Rodrigues, DN; Chénard-Poirier, M; Dolling, D; Clarke, M; Figueiredo, I; Bertan, C; Yuan, W; Ferreira, A; Chistova, R; Boysen, G; Perez, DR; Tunariu, N; Mateo, J; Wotherspoon, A; Chau, I; Cunningham, D; Valeri, N; Carreira, S; de Bono, J (2018-12)
      Background Loss of ataxia telangiectasia mutated (ATM), a key protein regulating DNA repair signaling, has been suggested to increase sensitivity to DNA damaging agents. We conducted a study analyzing the loss of ATM protein ...
    • Attitudes of Patients With Gastrointestinal Cancers Toward Research Biopsies. 

      Moorcraft, SY; Begum, R; Cunningham, D; Peckitt, C; Baratelli, C; Gillbanks, A; Rogers, P; Nwokorie, V; Chau, I; Watkins, D; Starling, N (2017-09)
      Background Research biopsies are an increasingly important component of clinical trials, but there are concerns that biopsies may deter patients from participating in research.Patients and methods Patients participating ...
    • Beyond genomics - Targeting the epigenome in diffuse large B-cell lymphoma. 

      Kühnl, A; Cunningham, D; Chau, I (2017-09)
      After decades of intense research on genetic alterations in cancer and successful implementation of genetically-based targeted therapies, the field of cancer epigenetics is only beginning to be fully recognized. The discovery ...
    • CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. 

      Gonzalez-Exposito, R; Semiannikova, M; Griffiths, B; Khan, K; Barber, LJ; Woolston, A; Spain, G; von Loga, K; Challoner, B; Patel, R; Ranes, M; Swain, A; Thomas, J; Bryant, A; Saffery, C; Fotiadis, N; Guettler, S; Mansfield, D; Melcher, A; Powles, T; Rao, S; Watkins, D; Chau, I; Matthews, N; Wallberg, F; Starling, N; Cunningham, D; Gerlinger, M (2019-04-15)
      Background The T cell bispecific antibody cibisatamab (CEA-TCB) binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells, which triggers T cell killing of cancer cell lines expressing moderate to high levels ...
    • Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre. 

      Athauda, A; Watkins, D; Mohammed, K; Chau, I; Starling, N; Rao, S; Tait, D; Aitken, K; Cunningham, D (2018-10)
      Background/aim Cisplatin-based radical chemoradiotherapy (CRT) is utilised in oesophagogastric (OG) cancer but the toxicity profile of cisplatin limits its use. This study aimed to evaluate the clinical characteristics and ...
    • Clonal diversity of MYC amplification evaluated by fluorescent in situ hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: Results from a prospective clinical trial screening programme. 

      Davidson, M; Aronson, LI; Howard-Reeves, J; Bryant, H; Cutts, RJ; Hulkki-Wilson, S; Kouvelakis, K; Kalaitzaki, E; Watkins, D; Starling, N; Rao, S; Cardenosa, ML; Begum, R; Rana, I; Lazaro-Alcausi, R; Terlizzo, M; Wotherspoon, A; Brown, G; Swansbury, J; Lord, CJ; Cunningham, D; Chau, I; Chong, IY (2019-11)
      Introduction The MYC proto-oncogene is among the most commonly dysregulated genes in human cancers. We report screening data from the iMYC trial, an ongoing phase II study assessing ibrutinib monotherapy in advanced ...
    • Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. 

      Sclafani, F; Brown, G; Cunningham, D; Wotherspoon, A; Mendes, LST; Balyasnikova, S; Evans, J; Peckitt, C; Begum, R; Tait, D; Tabernero, J; Glimelius, B; Roselló, S; Thomas, J; Oates, J; Chau, I (2017-11)
      Background Limited data exist regarding the correlation between MRI tumour regression grade (mrTRG) and pathological TRG (pTRG) in rectal cancer.Methods mrTRG and pTRG were compared in rectal cancer patients from two phase ...
    • Comparison of a coaxial versus non-coaxial liver biopsy technique in an oncological setting: diagnostic yield, complications and seeding risk. 

      Fotiadis, N; De Paepe, KN; Bonne, L; Khan, N; Riddell, A; Turner, N; Starling, N; Gerlinger, M; Rao, S; Chau, I; Cunningham, D; Koh, D-M (2020-12)
      Objectives Percutaneous liver biopsy (PLB) poses specific challenges in oncological patients such as bleeding and tumour seeding. This study's aim was to compare a coaxial (C-PLB) and non-coaxial (NC-PLB) biopsy technique ...
    • Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma. 

      Davidson, M; Barber, LJ; Woolston, A; Cafferkey, C; Mansukhani, S; Griffiths, B; Moorcraft, S-Y; Rana, I; Begum, R; Assiotis, I; Matthews, N; Rao, S; Watkins, D; Chau, I; Cunningham, D; Starling, N; Gerlinger, M (2019-05-27)
      DNA somatic copy number aberrations (SCNAs) are key drivers in oesophagogastric adenocarcinoma (OGA). Whether minimally invasive SCNA analysis of circulating tumour (ct)DNA can predict treatment outcomes and reveal how ...
    • Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data. 

      Khan, K; Gonzalez-Exposito, R; Cunningham, D; Koh, D-M; Woolston, A; Barber, L; Griffiths, B; Kouvelakis, K; Calamai, V; Bali, M; Khan, N; Bryant, A; Saffery, C; Dearman, C; Begum, R; Rao, S; Starling, N; Watkins, D; Chau, I; Braconi, C; Valeri, N; Gerlinger, M; Fotiadis, N (2020-01)
      Background Image-guided tissue biopsies are critically important in the diagnosis and management of cancer patients. High-yield samples are also vital for biomarker and resistance mechanism discovery through molecular/genomic ...
    • Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience. 

      Khan, K; Rane, JK; Cunningham, D; Rao, S; Watkins, D; Starling, N; Kalaitzaki, E; Forster, M; Braconi, C; Valeri, N; Gerlinger, M; Chau, I (2019-03)
      Background Gastrointestinal (GI) cancer patients may not be considered for therapy with fluoropyrimidines (FPs) because of previous cardiovascular (CV) toxicity or preexisting risk factors; such patients may benefit from ...
    • EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. 

      Smyth, EC; Vlachogiannis, G; Hedayat, S; Harbery, A; Hulkki-Wilson, S; Salati, M; Kouvelakis, K; Fernandez-Mateos, J; Cresswell, GD; Fontana, E; Seidlitz, T; Peckitt, C; Hahne, JC; Lampis, A; Begum, R; Watkins, D; Rao, S; Starling, N; Waddell, T; Okines, A; Crosby, T; Mansoor, W; Wadsley, J; Middleton, G; Fassan, M; Wotherspoon, A; Braconi, C; Chau, I; Vivanco, I; Sottoriva, A; Stange, DE; Cunningham, D; Valeri, N (2020-11-16)
      Objective Epidermal growth factor receptor (EGFR) inhibition may be effective in biomarker-selected populations of advanced gastro-oesophageal adenocarcinoma (aGEA) patients. Here, we tested the association between outcome ...
    • Exclusion of Gastrointestinal Cancer Patients With Prior Cancer From Clinical Trials: Is This Justified? 

      Smyth, EC; Tarazona, N; Peckitt, C; Armstrong, E; Mansukhani, S; Cunningham, D; Chau, I (2016-06)
      Background Strict eligibility criteria are necessary to maintain patient safety and scientific validity in clinical trials. However, this may lead to impaired generalizability of results. As survival in gastrointestinal ...
    • Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study 

      Fendler, A; Au, L; Shepherd, STC; Byrne, F; Cerrone, M; Boos, LA; Rzeniewicz, K; Gordon, W; Shum, B; Gerard, CL; Ward, B; Xie, W; Schmitt, AM; Joharatnam-Hogan, N; Cornish, GH; Pule, M; Mekkaoui, L; Ng, KW; Carlyle, E; Edmonds, K; Rosario, LD; Sarker, S; Lingard, K; Mangwende, M; Holt, L; Ahmod, H; Stone, R; Gomes, C; Flynn, HR; Agua-Doce, A; Hobson, P; Caidan, S; Howell, M; Wu, M; Goldstone, R; Crawford, M; Cubitt, L; Patel, H; Gavrielides, M; Nye, E; Snijders, AP; MacRae, JI; Nicod, J; Gronthoud, F; Shea, RL; Messiou, C; Cunningham, D; Chau, I; Starling, N; Turner, N; Welsh, L; van As, N; Jones, RL; Droney, J; Banerjee, S; Tatham, KC; Jhanji, S; O’Brien, M; Curtis, O; Harrington, K; Bhide, S; Bazin, J; Robinson, A; Stephenson, C; Slattery, T; Khan, Y; Tippu, Z; Leslie, I; Gennatas, S; Okines, A; Reid, A; Young, K; Furness, AJS; Pickering, L; Gandhi, S; Gamblin, S; Swanton, C; Nicholson, E; Kumar, S; Yousaf, N; Wilkinson, KA; Swerdlow, A; Harvey, R; Kassiotis, G; Larkin, J; Wilkinson, RJ; Turajlic, S
      <jats:title>Abstract</jats:title><jats:p>Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. ...
    • Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. 

      Khan, K; Rata, M; Cunningham, D; Koh, D-M; Tunariu, N; Hahne, JC; Vlachogiannis, G; Hedayat, S; Marchetti, S; Lampis, A; Damavandi, MD; Lote, H; Rana, I; Williams, A; Eccles, SA; Fontana, E; Collins, D; Eltahir, Z; Rao, S; Watkins, D; Starling, N; Thomas, J; Kalaitzaki, E; Fotiadis, N; Begum, R; Bali, M; Rugge, M; Temple, E; Fassan, M; Chau, I; Braconi, C; Valeri, N (2018-08)
      Objective Regorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC). Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns highlight the unmet need for better ...
    • Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. 

      Woolston, A; Khan, K; Spain, G; Barber, LJ; Griffiths, B; Gonzalez-Exposito, R; Hornsteiner, L; Punta, M; Patil, Y; Newey, A; Mansukhani, S; Davies, MN; Furness, A; Sclafani, F; Peckitt, C; Jiménez, M; Kouvelakis, K; Ranftl, R; Begum, R; Rana, I; Thomas, J; Bryant, A; Quezada, S; Wotherspoon, A; Khan, N; Fotiadis, N; Marafioti, T; Powles, T; Lise, S; Calvo, F; Guettler, S; von Loga, K; Rao, S; Watkins, D; Starling, N; Chau, I; Sadanandam, A; Cunningham, D; Gerlinger, M (2019-07)
      Despite biomarker stratification, the anti-EGFR antibody cetuximab is only effective against a subgroup of colorectal cancers (CRCs). This genomic and transcriptomic analysis of the cetuximab resistance landscape in 35 RAS ...
    • Genomic loss of heterozygosity and survival in the REAL3 trial. 

      Smyth, EC; Cafferkey, C; Loehr, A; Waddell, T; Begum, R; Peckitt, C; Harding, TC; Nguyen, M; Okines, AF; Raponi, M; Rao, S; Watkins, D; Starling, N; Middleton, GW; Wadsley, J; Mansoor, W; Crosby, T; Wotherspoon, A; Chau, I; Cunningham, D (2018-11-30)
      Background Homologous recombination deficiency (HRD) measured using a genomic signature for loss of heterozygosity (LOH) predicts benefit from rucaparib in ovarian cancer. We hypothesized that some oesophagogastric cancers ...
    • High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. 

      Pearson, A; Smyth, E; Babina, IS; Herrera-Abreu, MT; Tarazona, N; Peckitt, C; Kilgour, E; Smith, NR; Geh, C; Rooney, C; Cutts, R; Campbell, J; Ning, J; Fenwick, K; Swain, A; Brown, G; Chua, S; Thomas, A; Johnston, SRD; Ajaz, M; Sumpter, K; Gillbanks, A; Watkins, D; Chau, I; Popat, S; Cunningham, D; Turner, NC (2016-08)
      Unlabelled FGFR1 and FGFR2 are amplified in many tumor types, yet what determines response to FGFR inhibition in amplified cancers is unknown. In a translational clinical trial, we show that gastric cancers with high-level ...
    • Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours. 

      Young, K; Lawlor, RT; Ragulan, C; Patil, Y; Mafficini, A; Bersani, S; Antonello, D; Mansfield, D; Cingarlini, S; Landoni, L; Pea, A; Luchini, C; Piredda, L; Kannan, N; Nyamundanda, G; Morganstein, D; Chau, I; Wiedenmann, B; Milella, M; Melcher, A; Cunningham, D; Starling, N; Scarpa, A; Sadanandam, A (2020-09-03)
      <h4>Objective</h4>A comprehensive analysis of the immune landscape of pancreatic neuroendocrine tumours (PanNETs) was performed according to clinicopathological parameters and previously defined molecular subtypes to ...